Claims for Patent: 9,732,055

Summary for Patent: 9,732,055

Title:	Compositions and methods for cancer treatment
Abstract:	The present invention relates to the composition and methods of use of Stat3 pathway inhibitors or cancer stem cell inhibitors in combination treatment of cancer.
Inventor(s):	Li; Chiang Jia (Cambridge, MA), Mikule; Keith (Norwood, MA), Li; Youzhi (Westwood, MA)
Assignee:	Boston Biomedical, Inc. (Cambridge, MA)
Application Number:	12/677,516
Patent Claims:	1. A method for treating cancer in a human subject in need thereof comprising administering a composition comprising a therapeutically effective amount of at least one first agent chosen from 2-acetylnaphtho[2,3-b]furan-4,9-dione and pharmaceutically acceptable solvates thereof, wherein said 2-acetylnaphtho[2,3-b]furan-4,9-dione is synthetic and a composition comprising a therapeutically effective amount of at least one second agent chosen from growth factor-targeting agents, kinase-targeting agents, angiogenesis inhibitors, DNA-damaging agents, antimitotic agents, and antimetabolite agents, wherein said cancer is head and neck cancer, brain cancer, breast cancer, lung cancer, liver cancer, pancreatic cancer, ovarian cancer, cervical cancer, uterine cancer, gastrointestinal cancer, kidney cancer, bladder cancer, vulval cancer, cancer of the peritoneum, prostate cancer, thyroid cancer, sarcomas, squamous cell cancer, melanoma, leukemia, lymphoma, or myeloma, wherein said cancer expresses activated STAT3. 2. The method of claim 1, wherein the cancer is metastatic. 3. The method of claim 1, wherein the cancer is refractory to chemotherapy or radiotherapy. 4. The method of claim 1, wherein the cancer is resistant to chemotherapy. 5. The method of claim 1, wherein the cancer has relapsed. 6. The method of claim 1, wherein said cancer is head and neck cancer. 7. The method of claim 6, wherein said head and neck cancer is salivary gland cancer. 8. The method of claim 1, wherein said cancer is brain cancer. 9. The method of claim 8, wherein said brain cancer is glioblastoma. 10. The method of claim 1, wherein said cancer is breast cancer. 11. The method of claim 1, wherein said cancer is lung cancer. 12. The method of claim 11, wherein said lung cancer is small-cell lung cancer, non-small-cell lung cancer, adenocarcinoma of the lung, and/or squamous carcinoma of the lung. 13. The method of claim 1, wherein said cancer is liver cancer. 14. The method of claim 13, wherein said liver cancer is a hepatocellular carcinoma. 15. The method of claim 1, wherein said cancer is pancreatic cancer. 16. The method of claim 1, wherein said cancer is ovarian cancer. 17. The method of claim 1, wherein said cancer is uterine cancer. 18. The method of claim 1, wherein said uterine cancer is endometrial cancer. 19. The method of claim 1, wherein said cancer is cervical cancer. 20. The method of claim 1, wherein said cancer is gastrointestinal cancer. 21. The method of claim 20, wherein said gastrointestinal cancer is esophageal cancer, gastroesophageal junction cancer, gastric cancer, colon cancer, and/or colorectal cancer. 22. The method of claim 20, wherein said gastrointestinal cancer is esophageal and/or gastroesophageal junction cancer. 23. The method of claim 20, wherein said gastrointestinal cancer is gastric cancer. 24. The method of claim 20, wherein said gastrointestinal cancer is colon cancer. 25. The method of claim 20, wherein said gastrointestinal cancer is colorectal cancer. 26. The method of claim 1, wherein said cancer is cancer of the peritoneum. 27. The method of claim 1, wherein said cancer is kidney cancer. 28. The method of claim 27, wherein said kidney cancer is renal cell carcinoma. 29. The method of claim 1, wherein said cancer is bladder cancer. 30. The method of claim 1, wherein said cancer is vulval cancer. 31. The method of claim 1, wherein said cancer is prostate cancer. 32. The method of claim 1, wherein said cancer is thyroid cancer. 33. The method of claim 1, wherein said cancer is a sarcoma. 34. The method of claim 1, wherein said cancer is squamous cell cancer. 35. The method of claim 1, wherein said cancer is melanoma. 36. The method of claim 1, wherein said cancer is leukemia. 37. The method of claim 1, wherein said cancer is lymphoma. 38. The method of claim 1, wherein said cancer is myeloma. 39. The method of claim 38, wherein said myeloma is multiple myeloma. 40. The method of claim 1, wherein said at least one second agent is chosen from bevacizurnab, bortezomib, capecitabine, cetuximab, fluorouracil, imatinib, irinotecan, leucovorin, oxaliplatin, panitumumab, pemetrexed, temozolomide, cisplatin, paclitaxel, erlotinib, sunitinib, lapatinib, sorafenib, carboplatin, doxorubicin, docetaxel, gemcitabine, and etoposide. 41. The method of claim 1, wherein said at least one second agent is chosen from growth factor-targeting agents. 42. The method of claim 1, wherein said at least one second agent is chosen from Epidermal Growth Factor Receptor-targeting agents and Vascular Endothelial Growth Factor Receptor-targeting agents. 43. The method of claim 1, wherein said at least one second agent is chosen from gefitinib, PD153035, cetuximab, bevacizumab, panitumumab, trastuzumab, and anti-c-Met antibodies. 44. The method of claim 1, wherein said at least one second agent is chosen from kinase-targeting agents. 45. The method of claim 1, wherein said at least one second agent is chosen from kinase inhibitors. 46. The method of claim 1, wherein said at least one second agent is chosen from tyrosine kinase inhibitors. 47. The method of claim 1, wherein said at least one second agent is chosen from erlotinib, sunitinib, lapatinib, sorafenib, vandetanib, axitinib, bosutinib, cedivanib, dasatinib, gefitinib, imatinib, lestaurtinib, and ARQ197. 48. The method of claim 1, wherein said at least one second agent is chosen from gefitinib, ZD6474, EMD-72000, pariitumab, ICR-62, CI-1033, lapatinib, AEE788, EKB-569, EXEL 7647/EXEL 0999, erlotinib, imatinib, sorafinib, sunitinib, dasatinib, vandetinib, temsirolimus, PTK787, pazopanib, AZD2171, everolimus, seliciclib, AMG 706, axitinib, PD0325901, PKC-412, CEP701, XL880, bosutinib, BIBF1120, BIBF1120, nilotinib, AZD6244, HKI-272, MS-275, BI2536, GX15-070, AZD0530, enzastaurin, MLN-518, and ARQ197. 49. The method of claim 1, wherein said at least one second agent is chosen from erlotinib, lapatinib, and gefitinib. 50. The method of claim 1, wherein said at least one second agent is chosen from angiogenesis inhibitors. 51. The method of claim 1, wherein said at least one second agent is chosen from CM101, IFN-.alpha., IL-12, platelet factor-4, suramin, SU5416, thrombospondin, VEGFR antagonists, angiostatic steroids plus heparin, Cartilage-Derived Angiogenesis Inhibitory Factor, matrix metalloproteinase inhibitors, batimastat, marimastat, angiostatin, endostatin, 2-methoxyestradiol, tecogalan, thrombospondin, .alpha.V.beta.3 inhibitors, linomide, and ADH-1. 52. The method of claim 1, wherein said at least one second agent is chosen from DNA-damaging agents. 53. The method of claim 1, wherein said at least one second agent is chosen from alkylating agents, topoisomerase inhibitors, and DNA intercalators. 54. The method of claim 1, wherein said at least one second agent is chosen from alkylating agents. 55. The method of claim 1, wherein said at least one second agent is chosen from chlorambucil, cyclophosphamide, ifosfamide, mechlorethamine, melphalan, uracil mustard, thiotepa, busulfan, carmustine, lomustine, streptozocin, carboplatin, cisplatin, satraplatin, oxaliplatin, altretamine, ET-743, XL119, dacarbazine, chlormethine, bendamustine, trofosfamide, uramustine, fotemustine, nimustine, prednimustine, ranimustine, semustine, nedaplatin, triplatin tetranitrate, mannosulfan, treosulfan, temozolomide, carboquone, triaziquone, triethylenemelamine, and procarbazin. 56. The method of claim 1, wherein said at least one second agent is chosen from topoisomerase inhibitors. 57. The method of claim 1, wherein said at least one second agent is chosen from doxorubicin, daunorubicin, epirubicin, idarubicin, anthracenedione, mitoxantrone, mitomycin C, bleomycin, dactinomycin, plicatomycin, irinotecan, camptothecin, rubitecan, belotecan, etoposide, teniposide, and topotecan. 58. The method of claim 1, wherein said at least one second agent is chosen from DNA intercalators. 59. The method of claim 1, wherein said at least one second agent is chosen from proflavine, doxorubicin, daunorubicin, dactinomycin, and thalidomide. 60. The method of claim 1, wherein said at least one second agent is chosen from antimitotic agents. 61. The method of claim 1, wherein said at least one second agent is chosen from paclitaxel, taxol, docetaxel, BMS-275183, xyotax, tocosal, vinorlebine, vincristine, vinblastine, vindesine, vinzolidine, etoposide, teniposide, ixabepilone, larotaxel, ortataxel, tesetaxel, and ispinesib. 62. The method of claim 1, wherein said at least one second agent is chosen from antimetabolite agents. 63. The method of claim 1, wherein said at least one second agent is chosen from fluorouracil, floxuridine, methotrexate, xeloda, arranon, leucovorin, hydroxyurea, thioguanine, mercaptopurine, cytarabine, pentostatin, fludarabine phosphate, cladribine, asparaginase, gemcitabine, pemetrexed, bortezomib, aminopterin, raltitrexed, clofarabine, enocitabine, sapacitabine, and azacitidine. 64. The method of claim 1, wherein said at least one second agent is chosen from fluorouracil, methotrexate, capecitabine, leucovorin, gemcitabine, pemetrexed, and bortezomib. 65. The method of claim 1, wherein said at least one second agent is chosen from carboplatin, doxorubicin, gemcitabine, docetaxel, and etoposide. 66. The method of claim 1, wherein said at least one second agent is chosen from doxorubicin, irinotecan, and etoposide. 67. The method of claim 1, wherein said at least one second agent is chosen from carboplatin, cisplatin, satraplatin, oxaliplatin, nedaplatin, triplatin tetranitrate, temozolomide, or procarbazin, or any combination thereof. 68. The method of claim 1, wherein the second agent is chosen from paclitaxel, taxol, docetaxel, xyotax, tocosal, vinorlebine, vincristine, vinblastine, vindesine, vinzolidine, teniposide, ixabepilone, larotaxel, ortataxel, and tesetaxel. 69. The method of claim 1, wherein said at least one second agent is chosen from paclitaxel, taxol, docetaxel, xyotax, larotaxel, ortataxel, and tesetaxel. 70. The method of claim 1, wherein said at least one second agent is paclitaxel. 71. The method of claim 1, wherein said at least one second agent is temozolomide. 72. The method of claim 1, wherein said at least one second agent is doxorubicin. 73. The method of claim 1, comprising administering said composition comprising a therapeutically effective amount of at least one first agent and said composition comprising a therapeutically effective amount of at least one second agent to a human subject with cancer, wherein said cancer is head and neck cancer, brain cancer, breast cancer, lung cancer, liver cancer, pancreatic cancer, ovarian cancer, cervical cancer, uterine cancer, gastrointestinal cancer, kidney cancer, bladder cancer, vulval cancer, cancer of the peritoneum, prostate cancer, thyroid cancer, sarcomas, squamous cell cancer, melanoma, leukemia, lymphoma, or myeloma. 74. The method of claim 1, wherein said composition comprising a therapeutically effective amount of at least one first agent is chosen from compositions consisting of at least one first agent. 75. The method of claim 1, wherein said composition comprising a therapeutically effective amount of at least one first agent further comprises at least one pharmaceutically-acceptable excipient, carrier, or diluent. 76. The method of claim 75, where said at least one pharmaceutically-acceptable excipient, carrier, or diluent is chosen from Gelucire. 77. The method of claim 1, wherein said composition comprising a therapeutically effective amount of at least one second agent is chosen from compositions consisting of at least one second agent. 78. The method of claim 1, wherein said composition comprising a therapeutically effective amount of at least one second agent further comprises at least one pharmaceutically-acceptable excipient, carrier, or diluent. 79. The method of claim 78, where said at least one pharmaceutically-acceptable excipient, carrier, or diluent is chosen from Gelucire. 80. The method of claim 1, wherein said composition comprising a therapeutically effective amount of at least one first agent is formulated for oral administration. 81. The method of claim 1, wherein said composition comprising a therapeutically effective amount of at least one second agent is formulated for oral administration. 82. A method for treating cancer in a human subject in need thereof comprising administering to said subject a composition comprising a therapeutically effective amount of at least one first agent chosen from 2-acetylnaphtho[2,3-b]furan-4,9-dione and pharmaceutically acceptable solvates thereof, wherein said 2-acetylnaphtho[2,3-b]furan-4,9-dione is synthetic and a composition comprising a therapeutically effective amount of at least one second agent chosen from bevacizumab, bortezomib, capecitabine, cetuximab, fluorouracil, imatinib, irinotecan, leucovorin, oxaliplatin, panitumumab, pemetrexed, temozolomide, cisplatin, paclitaxel, erlotinib, sunitinib, lapatinib, sorafenib, carboplatin, doxorubicin, docetaxel, gemcitabine, and etoposide, wherein said cancer is head and neck cancer, brain cancer, breast cancer, lung cancer, liver cancer, pancreatic cancer, ovarian cancer, cervical cancer, uterine cancer, gastrointestinal cancer, kidney cancer, bladder cancer, vulval cancer, cancer of the peritoneum, prostate cancer, thyroid cancer, sarcoma, squamous cell cancer, melanoma, leukemia, lymphoma, or myeloma, wherein said cancer expresses activated STAT3. 83. The method of claim 82, wherein the cancer is metastatic, refractory to chemotherapy or radiotherapy, resistant to chemotherapy, or has relapsed. 84. A method for treating cancer in a human subject in need thereof comprising administering to said subject a composition comprising a therapeutically effective amount of at least one first agent chosen from 2-acetylnaphtho[2,3-b]furan-4,9-dione and pharmaceutically acceptable solvates thereof, wherein said 2-acetylnaphtho[2,3-b]furan-4,9-dione is synthetic and a composition comprising a therapeutically effective amount of at least one second agent chosen from carboplatin, etoposide, doxorubicin, docetaxel, and gemcitabine, wherein said cancer is head and neck cancer, brain cancer, breast cancer, lung cancer, liver cancer, pancreatic cancer, ovarian cancer, cervical cancer, uterine cancer, gastrointestinal cancer, kidney cancer, bladder cancer, vulval cancer, cancer of the peritoneum, prostate cancer, thyroid cancer, sarcoma, squamous cell cancer, melanoma, leukemia, lymphoma, or myeloma, wherein said cancer expresses activated STAT3. 85. The method of claim 84, wherein the cancer is metastatic, refractory to chemotherapy or radiotherapy, resistant to chemotherapy, or has relapsed. 86. A method for treating cancer in a human subject in need thereof comprising administering to said subject a composition comprising a therapeutically effective amount of at least one first agent chosen from 2-acetylnaphtho[2,3-b]furan-4,9-dione and pharmaceutically acceptable solvates thereof, wherein said 2-acetylnaphtho[2,3-b]furan-4,9-dione is synthetic and a composition comprising a therapeutically effective amount of paclitaxel, wherein said cancer is head and neck cancer, brain cancer, breast cancer, lung cancer, liver cancer, pancreatic cancer, ovarian cancer, uterine cancer, cervical cancer, gastrointestinal cancer, kidney cancer, bladder cancer, vulval cancer, cancer of the peritoneum, prostate cancer, thyroid cancer, sarcoma, squamous cell cancer, melanoma, leukemia, lymphoma, or myeloma, wherein said cancer expresses activated STAT3. 87. The method of claim 86, wherein said cancer is ovarian cancer, breast cancer, lung cancer, melanoma, gastrointestinal cancer, cervical cancer. 88. The method of claim 86, wherein said cancer is gastrointestinal cancer. 89. The method of claim 88, wherein said gastrointestinal cancer is esophageal cancer or gastroesophageal junction cancer. 90. The method of claim 88, wherein said cancer is colorectal cancer. 91. The method of claim 86, wherein the cancer is metastatic, refractory to chemotherapy or radiotherapy, resistant to chemotherapy, or has relapsed.

Details for Patent 9,732,055

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2027-09-10
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2027-09-10
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2027-09-10